Here is what the FDA has decided to do.  Just came out tonight!

 

 

Basically it is to alter the black box label with additional messages about monotherapy with tysabri versus multi-therapy in addition to Tysabri!

 

Yawn!  This will not change sales of Tysabri at all in the US.  its the only thing that provides patient relief.  they are more afraid of what will happen if they don't take it!

 

Now I await some jackass analysts to say this is damaging to the sales formula and try and drive this down!  It would all be a bunch of crap!

 

The markets not great currently.  In a decent market this should have at least a target of $20-22.

 

I'll hold my shares and see what the EU regulatory authorities say!

 

Kutz